Answers are grounded in this paper and cite their sources.
Lynch syndrome is the most common hereditary syndrome predisposing to endometrial cancer, but the mechanisms contributing to tumor development remain incompletely understood. This review aimed to summarise current evidence on the composition and potential pathogenic role of the microbiota in Lynch syndrome-associated endometrial cancer and to explore its clinical implications. A systematic literature search of PubMed/MEDLINE and Embase was conducted between October and November 2025 using predefined terms related to microbiota, carcinogenesis, endometrial cancer, and Lynch syndrome. Available evidence suggests that alterations in the microbiota may contribute to carcinogenesis through chronic inflammation, immune modulation, metabolic changes, and bacterial genotoxicity. Studies in Lynch syndrome carriers with endometrial or colorectal cancer report an increased abundance of potentially pro-inflammatory Gram-negative bacteria, including Bacteroides fragilis and Fusobacterium nucleatum, together with a reduction in short-chain fatty acid-producing bacteria such as Faecalibacterium, Blautia, and Butyrivibrio. Microbial metabolites, including butyrate, may have protective effects, whereas bacterial β-glucuronidase activity may increase estrogen bioavailability and contribute to a tumor-promoting environment. Emerging evidence also suggests that the microbiota may influence treatment response and toxicity. Overall, current evidence supports a potential role for the microbiota in Lynch syndrome-associated endometrial carcinogenesis, although data remain limited. Further studies are needed to determine whether microbiota profiling could contribute to risk stratification, prevention, and personalized therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Actis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: